ABVC Stock Overview
A clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ABVC BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.77 |
| 52 Week High | US$6.87 |
| 52 Week Low | US$0.67 |
| Beta | 0.71 |
| 11 Month Change | -12.05% |
| 3 Month Change | -40.92% |
| 1 Year Change | -85.10% |
| 33 Year Change | -98.28% |
| 5 Year Change | -99.36% |
| Change since IPO | -96.62% |
Recent News & Updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13
Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05Shareholder Returns
| ABVC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.6% | -0.3% | 0.3% |
| 1Y | -85.1% | 11.0% | 22.5% |
Return vs Industry: ABVC underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: ABVC underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| ABVC volatility | |
|---|---|
| ABVC Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ABVC's share price has been volatile over the past 3 months.
Volatility Over Time: ABVC's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Uttam Patil | www.abvcpharma.com |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.
ABVC BioPharma, Inc. Fundamentals Summary
| ABVC fundamental statistics | |
|---|---|
| Market cap | US$7.98m |
| Earnings (TTM) | -US$12.62m |
| Revenue (TTM) | US$25.36k |
330.4x
P/S Ratio-0.7x
P/E RatioIs ABVC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABVC income statement (TTM) | |
|---|---|
| Revenue | US$25.36k |
| Cost of Revenue | US$242.08k |
| Gross Profit | -US$216.71k |
| Other Expenses | US$12.41m |
| Earnings | -US$12.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | -854.45% |
| Net Profit Margin | -49,776.99% |
| Debt/Equity Ratio | 26.7% |
How did ABVC perform over the long term?
See historical performance and comparison